The GLP is committed to full transparency. Download and review our 2019 Annual Report

Myriad argues (again) for patents related to breast cancer genes

| | September 16, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Before a courtroom packed Wednesday with attorneys and company officials, Utah-based Myriad Genetics again defended its patents related to genes linked to breast and ovarian cancer from a new assault by two competitors hoping to move in on its lucrative area of genetic testing.

A bit less than three months after a U.S. Supreme Court decision invalidated several parts of Myriad patents related to the so-called BRCA1 and BRCA2 genes, Myriad was back in a federal courtroom asking a judge to prohibit two competitors from offering diagnostic DNA tests that detect mutations related to a high probability of contracting hereditary breast and ovarian cancers.

Read the full, original story here: “Utah’s Myriad argues (again) for patents related to breast cancer genes” 

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend